Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04480853 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Study acronym: SPRING
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. 3 versions Re-verified since Apr 3, 2026, no change to tracked fieldsv16-v18
  2. Site details revised at 1 of 6 sitesv15
  3. Primary and study completion dates: Jan 27, 2026 to Sep 30, 2027 Site details revised at 2 of 6 sitesv14 Show 1 more changeShow less
    • Site details revised at 2 of 6 sites
  4. Re-verified, no change to tracked fieldsv13
  5. Site details revised at 2 of 6 sitesv12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary and study completion dates: Feb 28, 2025 to Jan 27, 2026v11
  2. Site details revised at 1 of 6 sitesv10
  3. Primary completion date: Jul 15, 2024 to Feb 28, 2025 Study sites: 5 to 6 · Completion date: Oct 15, 2024 to Feb 28, 2025v9 Show 2 more changesShow less
    • Study sites: 5 to 6
    • Completion date: Oct 15, 2024 to Feb 28, 2025
  4. Primary completion date: Jul 15, 2022 to Jul 15, 2024 Completion date: Jul 15, 2022 to Oct 15, 2024v8 Show 1 more changeShow less
    • Completion date: Jul 15, 2022 to Oct 15, 2024
  5. Re-verified, no change to tracked fieldsv7
  6. Study sites: 4 to 5v6
  7. Study sites: 1 to 4v5
  8. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v4 Show 1 more changeShow less
    • Study sites: 0 to 1
  9. Start date: Sep 15, 2020 to Oct 12, 2020v3
  10. Start date: Aug 14, 2020 to Sep 15, 2020 Eligibility criteria revisedv2 Show 1 more changeShow less
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
Multiple Sclerosis
991 trials monitored
See 36 trials at risk
The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.
Trial Details
NCT Number NCT04480853
Lead Sponsor Novartis Pharmaceuticals
Conditions Multiple Sclerosis
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov